Contacto:

4. PUBLICATION OF ESDOM STUDY

Ingalfarma announces the recent publication of its Multicenter, Phase 2, Clinical Trial, for the Evaluation of the Efficacy and Safety of Dentoxol® in the prevention of oral mucositis in head and neck cancer patients in the international journal Supportive Care in Cancer. «It has been very gratifying and enriching to have achieved this milestone for … Leer más

5. DIARIO FINANCIERO HIGHLIGHTS THE USE OF DENTOXOL® IN POST-VENTILATED PATIENTS

Ingalfarma performs product tests on COVID-19 patients connected to mechanical ventilators, to treat oral lesions caused by connection to respirators, helping to lessen these adverse effects and help to recover, as soon as possible, their normal diet. «At Ingalfarma, we always want to contribute from the medical perspective of comprehensive management, in the recovery of … Leer más

6. GRANT OF CORFO FUNDS FOR INTERNATIONALIZATION

To support its 2020-2021 internationalization plan, Ingalfarma has been awarded a new CORFO fund called Consolidation and Expansion. “In order to enhance Chile’s entrepreneurial ecosystem, CORFO’s support of the last 10 years has been essential. This line of financing, in our opinion, goes in the right direction to continue accompanying StartUps beyond the seed stage, … Leer más

7. ISO 9001 CERTIFICATION

During the month of March 2020, Ingalfarma underwent the follow-up audit of the ISO 9001 certification, initially obtained in March 2019. The results of this audit carried out by the international certifying house AENOR, were satisfactory, allowing us to continue with our quality management system.